Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
- Suresh S. Ramalingam
- , Fiona Blackhall
- , Maciej Krzakowski
- , Carlos H. Barrios
- , Keunchil Park
- , Isabel Bover
- , Dae Seog Heo
- , Rafael Rosell
- , Denis C. Talbot
- , Richard Frank
- , Stephen P. Letrent
- , Ana Ruiz-Garcia
- , Ian Taylor
- , Jane Q. Liang
- , Alicyn K. Campbell
- , Joseph O'Connell
- , Michael Boyer
- Emory University
- The Christie NHS Foundation Trust
- Maria Sklodowska-Curie Institute of Oncology
- Pontifícia Universidade Católica do Rio Grande do Sul
- Hospital Universitario Son Llàtzer
- Seoul National University
- Institute Catala Oncologia
- University of Oxford
- Norwalk Hospital
- Pfizer
- Sydney Cancer Centre
Research output: Contribution to journal › Article › peer-review
257
Link opens in a new tab
Scopus
citations